Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic is well positioned because vidofludimus calcium has already shown Phase 2 activity in relapsing MS, including a reduction in mean cumulative combined unique active lesions from 6.4 with placebo to 2.4 at 24 weeks and durable disability control, with 92.3% of patients remaining free of 12-week confirmed disability worsening at week 144. Its dual mechanism, combining selective DHODH inhibition with Nurr1-driven neuroprotective potential, supports differentiation versus existing therapies in a large, heterogeneous MS market where progression remains an unmet need. The February 2026 PIPE added roughly $200MM in gross proceeds and may extend runway into late 2028, while extensive patent protection through 2044-2045 and upcoming ENSURE-1 and ENSURE-2 topline data later this year provide meaningful fundamental and catalyst support.

Immunic is a clinical-stage biopharmaceutical company whose valuation depends on unproven late-stage assets, leaving the shares exposed to binary clinical and regulatory outcomes in ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The fundamental bear case is amplified by financing risk, because the company must fund ongoing development while facing the possibility that lead programs do not demonstrate efficacy, safety, or commercial differentiation against entrenched competitors and current/future therapies. Despite a cash position of about $3.50 per share and a bear-case valuation below $8.73 per share, dilution from warrant exercise and additional capital needs could further pressure shareholder value if Phase 3 results fail to translate into durable sales.